Biotechgate Global Database ›
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Daix (France), Long Island City (New York, United States), July 19, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.
Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of June 30, 2023:
- Cash: € 285,764.46
- Number of shares: 129,659
- Number of executions on buy side on semester: 1,886
- Number of executions on sell side on semester: 1,610
- Traded volume on buy side on semester: 322,578 shares for € 1,074,534.26
- Traded volume on sell side on semester: 276,147 shares for € 938,985.90
At the last half-year report as of December 31, 2023, the following resources were available in the liquidity account:
- Cash: € 416,331.34
- Number of shares: 83,228
- Number of executions on buy side on semester: 828
- Number of executions on sell side on semester: 877
- Traded volume on buy side on semester: 157,508 shares for € 584,045.97
- Traded volume on sell side on semester: 180,395 shares for € 695,421.23
When the contract was initially implemented, the following resources were included in the liquidity account:
- Cash: € 163,510.42
- Number of shares: 34,063
| Buy Side | Sell Side | |||||||
| Number of executions | Number of shares | Traded volume in EUR | Number of executions | Number of shares | Traded volume in EUR | |||
| Total | 1 886 | 322 578 | 1 074 534,26 | 1 610 | 276 147 | 938 985,90 | ||
| 01/02/2024 | 15 | 2 500 | 10 275,00 | 19 | 3 507 | 14 589,12 | ||
| 01/03/2024 | 5 | 1 000 | 4 140,00 | 2 | 1 000 | 4 190,00 | ||
| 01/04/2024 | 9 | 2 500 | 10 425,00 | 15 | 4 793 | 20 561,97 | ||
| 01/05/2024 | 11 | 2 463 | 9 999,78 | - | - | - | ||
| 01/08/2024 | 5 | 1 500 | 6 165,00 | 10 | 3 373 | 13 997,95 | ||
| 01/09/2024 | 15 | 3 522 | 14 193,66 | 4 | 1 240 | 5 096,40 | ||
| 01/10/2024 | 12 | 2 978 | 11 971,56 | 5 | 1 024 | 4 126,72 | ||
| 01/11/2024 | 21 | 6 499 | 25 021,15 | - | - | - | ||
| 01/12/2024 | 3 | 1 500 | 5 625,00 | 8 | 2 000 | 7 720,00 | ||
| 01/15/2024 | 15 | 3 500 | 12 705,00 | 2 | 282 | 1 026,48 | ||
| 01/16/2024 | 14 | 2 000 | 7 160,00 | 2 | 501 | 1 803,60 | ||
| 01/17/2024 | 23 | 3 427 | 11 891,69 | 2 | 192 | 683,52 | ||
| 01/18/2024 | 13 | 3 073 | 10 386,74 | 13 | 3 000 | 10 230,00 | ||
| 01/19/2024 | 2 | 500 | 1 700,00 | 6 | 1 250 | 4 275,00 | ||
| 01/22/2024 | 13 | 3 000 | 10 230,00 | 8 | 1 500 | 5 235,00 | ||
| 01/23/2024 | 3 | 1 500 | 5 115,00 | 16 | 4 716 | 16 694,64 | ||
| 01/24/2024 | 6 | 2 000 | 7 040,00 | 9 | 1 100 | 3 894,00 | ||
| 01/25/2024 | 8 | 1 500 | 5 265,00 | 1 | 1 | 3,56 | ||
| 01/26/2024 | 8 | 1 600 | 5 616,00 | 4 | 1 499 | 5 321,45 | ||
| 01/29/2024 | 10 | 1 000 | 3 530,00 | 7 | 2 054 | 7 291,70 | ||
| 01/30/2024 | 9 | 2 500 | 8 825,00 | 9 | 1 836 | 6 536,16 | ||
| 01/31/2024 | 12 | 2 751 | 9 600,99 | 10 | 1 302 | 4 570,02 | ||
| 02/01/2024 | 13 | 4 000 | 13 840,00 | 4 | 1 000 | 3 500,00 | ||
| 02/02/2024 | 13 | 3 001 | 10 293,43 | 5 | 1 030 | 3 574,10 | ||
| 02/05/2024 | 13 | 3 096 | 10 619,28 | 12 | 4 971 | 17 199,66 | ||
| 02/06/2024 | 19 | 2 904 | 9 931,68 | 7 | 2 000 | 6 900,00 | ||
| 02/07/2024 | 25 | 6 000 | 19 980,00 | 1 | 50 | 173,00 | ||
| 02/08/2024 | 8 | 1 500 | 4 875,00 | 10 | 1 314 | 4 296,78 | ||
| 02/09/2024 | 11 | 2 000 | 6 380,00 | 11 | 1 500 | 4 845,00 | ||
| 02/12/2024 | 13 | 1 750 | 5 810,00 | 31 | 8 636 | 29 103,32 | ||
| 02/13/2024 | 17 | 3 587 | 12 303,41 | 15 | 2 750 | 9 542,50 | ||
| 02/14/2024 | 12 | 2 250 | 7 807,50 | 18 | 3 629 | 12 737,79 | ||
| 02/15/2024 | 10 | 2 000 | 7 000,00 | 26 | 4 939 | 17 533,45 | ||
| 02/16/2024 | 44 | 10 663 | 31 882,37 | 13 | 2 500 | 7 625,00 | ||
| 02/19/2024 | 19 | 2 137 | 6 624,70 | 29 | 4 750 | 14 962,50 | ||
| 02/20/2024 | 25 | 3 613 | 11 091,91 | 7 | 1 001 | 3 123,12 | ||
| 02/21/2024 | 9 | 1 760 | 5 332,80 | 3 | 351 | 1 084,59 | ||
| 02/22/2024 | 13 | 1 721 | 5 231,84 | 2 | 251 | 773,08 | ||
| 02/23/2024 | 24 | 3 770 | 11 196,90 | 1 | 250 | 750,00 | ||
| 02/26/2024 | 15 | 2 250 | 6 592,50 | 12 | 2 250 | 6 660,00 | ||
| 02/27/2024 | 13 | 2 250 | 6 772,50 | 38 | 5 167 | 16 017,70 | ||
| 02/28/2024 | 14 | 2 010 | 6 130,50 | 21 | 3 732 | 11 755,80 | ||
| 02/29/2024 | 15 | 2 000 | 6 320,00 | 8 | 1 250 | 3 987,50 | ||
| 03/01/2024 | 12 | 2 029 | 6 492,80 | 20 | 3 500 | 11 410,00 | ||
| 03/04/2024 | 15 | 2 501 | 8 228,29 | 21 | 4 251 | 14 283,36 | ||
| 03/05/2024 | 23 | 3 500 | 11 725,00 | 28 | 2 308 | 7 916,44 | ||
| 03/06/2024 | 28 | 3 749 | 12 221,74 | 9 | 1 458 | 4 796,82 | ||
| 03/07/2024 | 14 | 1 573 | 5 112,25 | 12 | 2 500 | 8 250,00 | ||
| 03/08/2024 | 21 | 3 997 | 13 190,10 | 25 | 4 601 | 15 505,37 | ||
| 03/11/2024 | 16 | 2 250 | 7 560,00 | 20 | 2 999 | 10 196,60 | ||
| 03/12/2024 | 13 | 1 956 | 6 787,32 | 28 | 3 900 | 13 728,00 | ||
| 03/13/2024 | 10 | 1 530 | 5 355,00 | 24 | 2 500 | 8 875,00 | ||
| 03/14/2024 | 22 | 4 250 | 15 172,50 | 31 | 6 000 | 21 840,00 | ||
| 03/15/2024 | 16 | 2 000 | 7 320,00 | 39 | 4 750 | 17 622,50 | ||
| 03/18/2024 | 18 | 2 000 | 7 560,00 | 37 | 5 500 | 21 010,00 | ||
| 03/19/2024 | 101 | 20 564 | 75 881,16 | 34 | 6 863 | 28 550,08 | ||
| 03/20/2024 | 31 | 5 750 | 18 802,50 | 11 | 1 770 | 5 876,40 | ||
| 03/21/2024 |
By: GlobeNewswire
- 19 Jul 2024
Return to news
Partners
Upcoming Life Sciences Events
| |||||||
